Compounding Pharmacy · Chandler, AZ · 503B

Tailstorm Health (Medivant Health) Review

Tailstorm Health Inc., doing business as Medivant Health, is an FDA-registered 503B outsourcing facility in the Phoenix/Chandler, Arizona area that compounded sterile semaglutide and tirzepatide injections. It received an FDA warning letter in April 2025 for cGMP and sterility violations and missing labeling on its GLP-1 products.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

503BFDA Registered 503B
Location: Chandler, AZ
States licensed: 0
5.0
Weight Loss Rankings Score
out of 10

About this pharmacy

Tailstorm Health Inc., doing business as Medivant Health, is an FDA-registered 503B outsourcing facility in the Phoenix/Chandler, Arizona area that compounded sterile semaglutide and tirzepatide injections. It received an FDA warning letter in April 2025 for cGMP and sterility violations and missing labeling on its GLP-1 products.

Certifications & Compliance

All sterile compounding pharmacies in the United States are required to follow United States Pharmacopeia General Chapter <797> sterile compounding standards[4], with finished preparations evaluated against USP <71> sterility testing[5] and USP <85> bacterial endotoxin testing[6] as appropriate for the product type.

FDA Registered 503B
Registered directly with the FDA as a 503B outsourcing facility. Subject to FDA inspection and required to follow cGMP standards.

Drugs Produced

Compounding pharmacies' ability to produce semaglutide or tirzepatide depends on the FDA Drug Shortage List status for each reference product; compounding eligibility can change when a drug moves on or off the shortage list[7].

Yes
Semaglutide
Compounded semaglutide produced
Yes
Tirzepatide
Compounded tirzepatide produced

States Licensed (0)

Regulatory Actions

2025-04-08
FDA Warning Letter (FEI 703497) issued to Tailstorm Health Inc. dba Medivant Health following a Sept-Oct 2024 inspection, citing cGMP violations resulting in adulterated products, sterile products prepared under unsanitary conditions, missing required label statements on Semaglutide and Tirzepatide injections, and failure to submit adverse event reports.

Weight Loss Rankings Score Breakdown

Accreditation & Compliance6/10
Regulatory Standing5/10
State Coverage0/10
GLP-1 Production10/10
Track Record5/10

Scores are independently researched. See our methodology for details.

High confidence · Last verified 2026-06-04 via manual · How we verify provider data

Frequently Asked Questions

Glossary references

Key terms in this article, linked to their canonical definitions.

Sources & methodology — as of June 2026
  1. 1.FDA — Compounding and the 503A Pharmacy FrameworkU.S. Food & Drug Administration.
  2. 2.FDA — 503B Outsourcing Facility Registration and RequirementsU.S. Food & Drug Administration.
  3. 3.PCAB — Pharmacy Compounding Accreditation Board StandardsAccreditation Commission for Health Care (ACHC) / PCAB.
  4. 4.USP General Chapter <797> — Pharmaceutical Compounding: Sterile PreparationsUnited States Pharmacopeia.
  5. 5.USP General Chapter <71> — Sterility TestsUnited States Pharmacopeia.
  6. 6.USP General Chapter <85> — Bacterial Endotoxins TestUnited States Pharmacopeia.
  7. 7.FDA — Drug Shortages Database (current shortage listings)U.S. Food & Drug Administration.